DC Chemicals Limited
China
Product Name: WEHI-539
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

1431866-33-9

1431866-33-9 structure

1431866-33-9 structure

Name: WEHI-539
Chemical Name: 5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[(8E)-8-(1,3-benzothiazol-2-ylhydrazinylidene)-6,7-dihydro-5H-naphthalen-2-yl]-1,3-thiazole-4-carboxylic acid
CAS Number: 1431866-33-9
Molecular Formula: C₃₁H₂₉N₅O₃S₂
Molecular Weight: 583.724
Catalog: Signaling Pathways Apoptosis Bcl-2 Family
Create Date: 2017-05-08 03:38:58
Modify Date: 2024-01-13 17:36:20
WEHI-539 is a selective inhibitor of Bcl-XL with IC50 of 1.1 nM.

Name	5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[(8E)-8-(1,3-benzothiazol-2-ylhydrazinylidene)-6,7-dihydro-5H-naphthalen-2-yl]-1,3-thiazole-4-carboxylic acid
Synonyms	WEHI-539 5-(3-(4-(Aminomethyl)phenoxy)propyl)-2-(8-(2-(benzo[d]thiazol-2-yl)hydrazono)-5,6,7,8-tetrahydronaphthalen-2-yl)thiazole-4-carboxylic acid CS-1330 WEHI-539\|\|WEHI 539 4-Thiazolecarboxylic acid, 5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[(8E)-8-[2-(2-benzothiazolyl)hydrazinylidene]-5,6,7,8-tetrahydro-2-naphthalenyl]- 5-{3-[4-(Aminomethyl)phenoxy]propyl}-2-[(8E)-8-(1,3-benzothiazol-2-ylhydrazono)-5,6,7,8-tetrahydro-2-naphthalenyl]-1,3-thiazole-4-carboxylic acid

Description	WEHI-539 is a selective inhibitor of Bcl-XL with IC50 of 1.1 nM.
Related Catalog	Signaling Pathways >> Apoptosis >> Bcl-2 Family Research Areas >> Cancer
Target	Bcl-xL:1.1 nM (IC50)
In Vitro	WEHI-539 is a selective inhibitor of Bcl-XL. WEHI-539 augments Carboplatin induced caspase 3/7 activity, PARP cleavage and annexin V labelling. WEHI-539 as a single agent causes noticeable PARP cleavage in Ovcar-4 (5 μM in Ovcar-4.) and Ovsaho (1 μM in Ovsaho) cells[2].
Cell Assay	Ovcar-8, Ovcar-3, Ovcar-4 and Ovsaho cells are grown in the RPMI, Igrov-1, Cov-362 and Cov-318 cells are grown in DMEM and Fuov-1 cells are grown in DMEM/F-12 nutrient mixture. ABT-737, ABT-199 and WEHI-539 (Medchem Express, NJ, USA), are prepared as a 20 mM solution in DMSO. For cell growth assays, cells are plated in 96 wells plate (5,000 cells/well for all cell lines except Ovcar-8 which is plated at a density of 2,500 cells/well). The next day, cells are treated with drugs. After 72 h the culture medium is removed and the cells are fixed with 100 μL of cold 10 % Trichloroacetic acid (TCA), incubated on ice for 30 min and stained with 0.4 % sulforhodamine B (SRB). The data are analysed by using Graphpad Prism 4 software. Non-linear regression is used to fit a four parameters Hill equation. For drug combinations studies the cells are exposed simultaneously to a range of concentrations of carboplatin combined with fixed concentration of BH3 mimetics that is expected from the single agent studies to cause 5 % growth inhibition: ABT-737, 1 μM in Ovcar-8, Ovcar-3 and Igrov-1, 2 μM in Ovcar-4 and Ovsaho and 6 μM in Cov-362; ABT-199, 1 μM in Ovcar-4, 2 μM in Ovcar-3, Igrov-1, Cov-362 and Ovsaho and 3 μM in Ovcar-8; WEHI-539, 0.2 μM in Igrov-1, 0.3 μM in Ovcar-8, 1 μM in Ovcar-3 and Ovsaho, 3.1 μM in Cov-362 and 5 μM in Ovcar-4. Surviving cell number is assessed by SRB staining. A combination index (CI) is calculated[2].
References	[1]. Lessene G, et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 2013 Jun;9(6):390-7. [2]. Abed MN, et al. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J Ovarian Res. 2016 Apr 14;9:25.

Density	1.4±0.1 g/cm3
Boiling Point	827.6±75.0 °C at 760 mmHg
Molecular Formula	C₃₁H₂₉N₅O₃S₂
Molecular Weight	583.724
Flash Point	454.3±37.1 °C
Exact Mass	583.171204
PSA	179.20000
LogP	6.85
Vapour Pressure	0.0±3.2 mmHg at 25°C
Index of Refraction	1.737
Storage condition	2-8℃